SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer Breast 2 Mins Read51 The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
